G100 is a newer drug that harnesses the power of your own immune system and allows it to recognise and kill lymphoma cells. It is injected directly into tumours. Different doses of G100 are being tested in a phase 1/2 trial. Some people had radiotherapy and G100 while others had radiotherapy and both G100 and another newer drug, pembrolizumab. People with different types of lymphoma could enter early parts of the trial but the trial treatments have been tested in more people with follicular lymphoma.
Early results from people with follicular lymphoma treated as part of the trial were presented at the annual American Society of Hematology (ASH) meeting in December 2017.
Thirty-six people had been treated as part of the trial when the results were analysed. The safety of G100 was very encouraging, with most people having mild or moderate side effects. Adding pembrolizumab did not cause any unexpected side effects.
Around half of the participants had some response to treatment, with the tumour shrinking by at least a quarter in size. Only 13 people have been treated with the combination of G100 and pembrolizumab so far but the proportion of people having a good response to treatment appears to be higher for the combination treatment than for G100 alone. Follow-up continues for all of the participants in the trial to find out whether these responses are long-lasting and whether the responses improve over time.